[go: up one dir, main page]

WO2018144093A3 - Formulations pour soins de la peau améliorés - Google Patents

Formulations pour soins de la peau améliorés Download PDF

Info

Publication number
WO2018144093A3
WO2018144093A3 PCT/US2017/059960 US2017059960W WO2018144093A3 WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3 US 2017059960 W US2017059960 W US 2017059960W WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
collagen
formulations
skin care
improved skin
Prior art date
Application number
PCT/US2017/059960
Other languages
English (en)
Other versions
WO2018144093A2 (fr
Inventor
Mark A. Pinsky
Original Assignee
Pinsky Mark A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinsky Mark A filed Critical Pinsky Mark A
Publication of WO2018144093A2 publication Critical patent/WO2018144093A2/fr
Publication of WO2018144093A3 publication Critical patent/WO2018144093A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des procédés d'administration de collagène et/ou d'acide hyaluronique à un sujet humain. Les vésicules lipidiques contenant du collagène et/ou de l'acide hyaluronique de l'invention fournissent un système d'administration de protéine de collagène et/ou d'acide hyaluronique qui améliore significativement l'état de la peau d'un sujet humain tout en éliminant les problèmes associés à l'instabilité chimique et physique du collagène et/ou de l'acide hyaluronique ainsi que des réponses immunitaires associées.
PCT/US2017/059960 2016-11-03 2017-11-03 Formulations pour soins de la peau améliorés Ceased WO2018144093A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416987P 2016-11-03 2016-11-03
US62/416,987 2016-11-03

Publications (2)

Publication Number Publication Date
WO2018144093A2 WO2018144093A2 (fr) 2018-08-09
WO2018144093A3 true WO2018144093A3 (fr) 2019-03-07

Family

ID=63040032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/059960 Ceased WO2018144093A2 (fr) 2016-11-03 2017-11-03 Formulations pour soins de la peau améliorés

Country Status (1)

Country Link
WO (1) WO2018144093A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
BR112020024768A8 (pt) 2018-06-04 2022-12-13 Arcutis Inc Método para reduzir o intervalo de penetração cutânea de roflumilaste em um paciente, composição farmacêutica compreendendo roflumilaste e uma mistura emulsificante e composição farmacêutica compreendendo roflumilaste e pelo menos um emulsificante
CA3135835A1 (fr) * 2019-04-01 2020-10-08 Geltor, Inc. Formulations topiques de collagenes recombines
JP2022526434A (ja) 2019-04-12 2022-05-24 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
US11786451B2 (en) 2019-06-28 2023-10-17 The Procter & Gamble Company Skin care composition
US20200405621A1 (en) * 2019-06-28 2020-12-31 The Procter & Gamble Company Skin Care Composition
WO2021019562A2 (fr) * 2019-07-26 2021-02-04 Pandorum Technologies Private Limited Formulation obtenue par génie biologique, son procédé de préparation et ses mises en œuvre
EP3968948A1 (fr) * 2019-07-29 2022-03-23 Giuliani S.p.A. Composition cosmétique à charge combinée et effet régénérateur cutané
JP2022549216A (ja) 2019-09-23 2022-11-24 ディーディーエス リサーチ インク． 浸透促進剤を含有する脂質ベシクル組成物
CN111036156A (zh) * 2020-01-14 2020-04-21 江苏罗格斯生物科技有限公司 一种绿色功能因子精准控制材料的制备方法
CN111281840B (zh) * 2020-02-13 2022-03-29 广州伊尔美生物科技有限公司 一种亮颜美肤霜及其制备方法
CN114641297B (zh) * 2020-05-07 2024-09-13 阿尔库缇斯生物疗法股份有限公司 使用高克拉夫特温度阴离子表面活性剂治疗皮肤病症
CN111494233B (zh) * 2020-06-02 2023-07-14 康珞生物科技（武汉）有限公司 一种胶原短肽脂质体的制备方法及应用
CN112057351B (zh) * 2020-09-22 2023-01-24 西安诗莱梦特生物科技有限公司 透明质酸-羟丙基甲基纤维素复合水凝胶及其制备方法和应用
KR20230128261A (ko) * 2020-09-30 2023-09-04 젤터, 인코포레이티드 콜라겐 또는 엘라스틴 폴리펩티드와 활성 성분의 조합을 포함하는 조성물 및 이의 사용 방법
CN116669696A (zh) * 2020-09-30 2023-08-29 格尔托公司 包含胶原或弹性蛋白多肽与活性成分的组合的组合物及其使用方法
CA3162675C (fr) 2020-12-04 2023-09-26 Saori Kato Formulation topique de roflumilast presentant des proprietes antifongiques
CN114246818A (zh) * 2021-03-08 2022-03-29 山东祥隆医药研究院有限公司 一种具有防敏、保湿、修复功效的精华乳及其制备方法
WO2022204287A1 (fr) * 2021-03-24 2022-09-29 Glo Pharma, Inc. Vésicules lipidiques multisomes pour l'administration d'agents cosmétiques
CA3213099A1 (fr) 2021-03-24 2022-09-29 Robert A. Love Peptides et procedes de reduction de la pigmentation de la peau
CN120166935A (zh) 2022-09-15 2025-06-17 阿尔库缇斯生物疗法股份有限公司 罗氟司特和能够溶解大量该药物的溶剂的药物组合物
CN116617146B (zh) * 2023-05-26 2024-12-17 广东巴松那生物科技有限公司 一种用于修复激素脸的护肤霜及其制备方法
CN117137840A (zh) * 2023-09-07 2023-12-01 河北纳科生物科技有限公司 一种重组胶原蛋白水油双相精华油及其制备方法
CN117017869B (zh) * 2023-09-15 2024-01-30 名宇(广东)化妆品科技有限公司 一种美白祛斑霜及制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (ko) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 콜라겐 수식 리포솜으로 이루어지는 화장료 기제 및 그것을 함유하는 피부 화장료
CN102988200A (zh) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 脂质体养颜护肤品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (ko) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 콜라겐 수식 리포솜으로 이루어지는 화장료 기제 및 그것을 함유하는 피부 화장료
CN102988200A (zh) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 脂质体养颜护肤品

Also Published As

Publication number Publication date
WO2018144093A2 (fr) 2018-08-09

Similar Documents

Publication Publication Date Title
WO2018144093A3 (fr) Formulations pour soins de la peau améliorés
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2009086504A3 (fr) Formulations à base de collagène destinées à un soin cutané amélioré
EP4421094A3 (fr) Agents thérapeutiques ciblés et leurs utilisation
SG11201808019WA (en) Edaravone formulations
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MY188139A (en) Sodium channel modulators for the treatment of pain
IN2014CN04187A (fr)
EP4299122A3 (fr) Compositions et méthodes de traitement de maladies de la peau et des muqueuses
MX2020005247A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
WO2019098759A3 (fr) Cellule humaine transformée et son utilisation
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
IN2014DN03213A (fr)
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EP4420722A3 (fr) Facteurs de croissance des fibroblastes modifiés pour le traitement de troubles oculaires
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
EP4403220A3 (fr) Administration efficace de lipides à un film lacrymal humain à l'aide d'un système d'émulsion sensible au sel
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17895323

Country of ref document: EP

Kind code of ref document: A2